Paeds Vivas · neurology-neurodisability-and-neuromuscular
Sleep disorders with neurological disease: Viva
Branching clinical structured oral on sleep disorders with neurological disease: applying the four-cluster classification, building the targeted investigation pathway from polysomnography to the multiple sleep latency test and cerebrospinal fluid orexin, distinguishing nocturnal frontal lobe epilepsy from a parasomnia, and defending the stepped management built on sleep hygiene and behavioural therapy with melatonin, iron, airway support, and ventilation.
On this page
Study tools
Target exams
Opening question
Examiner: This boy with autism takes two hours to settle and wakes through the night. How do you approach the assessment, and what is the most likely category of sleep disorder here?
[9]Candidate: I would start with a structured sleep history and a two-week sleep diary, asking separately about sleep onset latency, night wakings and their triggers, total duration, morning mood, and the daytime impact on behaviour and learning. In a child with autism, the most likely category is a dyssomnia, specifically chronic insomnia of the neurodevelopmental disorders, because bedtime resistance and night-waking are the commonest sleep complaint in autism, occurring in 40 to 80 per cent of these children. I would use the Sleep Disturbance Scale for Children to screen for the other clusters and to track response, because a sleep disorder here is the expected finding, not the exception. [9]
Examiner: Good. Before you reach for a drug, what non-pharmacological measures would you put in place? [9]
Candidate: The foundation for every child is sleep hygiene and behavioural therapy, and this layer alone resolves a large fraction of chronic insomnia, so it must never be skipped. I would build a consistent bedtime routine, a regular rise time, removal of screens and caffeine from the evening, and a behavioural programme such as graduated extinction or sleep scheduling, adapted to his developmental level and supported by his parents and his school team. [9]
References8ShowHide
- [1]Scammell TE Narcolepsy. N Engl J Med, 2015.PMID 26716917
- [2]Gringras P, Nir T, Breddy J, et al Efficacy and safety of pediatric prolonged-release melatonin for insomnia in children with autism spectrum disorder. J Am Acad Child Adolesc Psychiatry, 2017.PMID 29096777
- [3]Maras A, Schroder CM, Malow BA, et al Long-term efficacy and safety of pediatric prolonged-release melatonin for insomnia in children with autism spectrum disorder. J Child Adolesc Psychopharmacol, 2018.PMID 30132686
- [5]DelRosso LM, Ferri R, Chen ML, et al Clinical efficacy and safety of intravenous ferric carboxymaltose treatment of pediatric restless legs syndrome and periodic limb movement disorder. Sleep Med, 2021.PMID 34562823
- [7]Vanhaverbeke K, Selçuk M, Ersu R, et al. Sleep-disordered breathing in children with neurodisabilities. Eur Respir Rev, 2026.PMID 42128483
- [9]Wang H, Yu L, Hu S, et al Prevalence and associated factors of sleep disorders in children and adolescents with autism spectrum disorder: a meta-analysis and systematic review. BMC Psychiatry, 2026.PMID 42192550
- [11]Berry RB, Brooks R, Gamaldo C, et al AASM Scoring Manual updates for 2017 (version 2.4). J Clin Sleep Med, 2017.PMID 28416048
- [12]Dauvilliers Y, Mignot E, Del Rio Villegas R, et al Oral orexin receptor 2 agonist in narcolepsy type 1. N Engl J Med, 2023.PMID 37494485